VISCHER advises Mind-NRG, in Geneva, in the sale of Mind-NRG to Minerva Neurosciences. Mind-NRG's main asset is MIN-301, a compound in development for the treatment of patients suffering from Parkinson's disease. The team at VISCHER is led by Matthias Staehelin (Corporate) with Janusz Marty.